Resolvin E1, resolvin D1 and resolvin D2 inhibit constriction of rat thoracic aorta and human pulmonary artery induced by the thromboxane mimetic U46619

No abstract is available for this paper.

• Publication year

  2018

• Venue

  British Journal of Pharmacology

• Publication date

  2018-04-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1111/bph.14151PMID 29352769PMCID PMC5843708
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Resolvin E1, resolvin D1 and resolvin D2 inhibit constriction of rat thoracic aorta and human pulmonary artery induced by the thromboxane mimetic U46619

  2018cited by this paper
• Chemerin-induced arterial contraction is Gi- and calcium-dependent.

  2017cited by this paper
• Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury

  2017cited by this paper
• The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

  2017cited by this paper
• THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein‐coupled receptors

  2017cited by this paper
• Experimental design and analysis and their reporting: new guidance for publication in BJP

  2015cited by this paper
• Resolvin E1 normalizes contractility, Ca2+ sensitivity and smooth muscle cell migration rate in TNF-α- and IL-6-pretreated human pulmonary arteries.

  2015cited by this paper
• Identification of resolvin D2 receptor mediating resolution of infections and organ protection

  2015influential reference
• Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP

  2015cited by this paper
• The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution.

  2015influential reference
• Resolution of inflammation: targeting GPCRs that interact with lipids and peptides

  2014cited by this paper
• Prenatal development is linked to bronchial reactivity: epidemiological and animal model evidence

  2014cited by this paper
• D‐series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury

  2013cited by this paper
• Resolvin D1 and Aspirin-Triggered Resolvin D1 Regulate Histamine-stimulated Conjunctival Goblet Cell Secretion

  2013cited by this paper
• Chemerin Connects Fat to Arterial Contraction

  2013influential reference
• This information is current as Inflammatory Tone in Obese Fat Resolvin D 1 and Resolvin D 2 Govern Local and

  2012cited by this paper
• Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation.

  2011cited by this paper
• Resolvin D1 binds human phagocytes with evidence for proresolving receptors

  2010cited by this paper
• Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines

  2010cited by this paper
• Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis.

  2010cited by this paper
• Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis

  2009cited by this paper
• Resolvin E1 Receptor Activation Signals Phosphorylation and Phagocytosis*

  2009influential reference
• Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets.

  2008cited by this paper
• Resolvin E1 Selectively Interacts with Leukotriene B4 Receptor BLT1 and ChemR23 to Regulate Inflammation1

  2007cited by this paper
• Resolvin D1 and Its Aspirin-triggered 17R Epimer

  2007cited by this paper
• Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1

  2005cited by this paper
• The C-terminal Nonapeptide of Mature Chemerin Activates the Chemerin Receptor with Low Nanomolar Potency*

  2004cited by this paper
• Resolvins

  2002influential reference
• Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2–Nonsteroidal Antiinflammatory Drugs and Transcellular Processing

  2000influential reference

• GPR18 Deletion in Mice Inversely Affects Vasoactive Signaling and Passive Biomechanical Properties of the Thoracic Aorta and Femoral Artery

  2026cites this paper
• Role of Inflammatory and Proresolving Mediators in Endothelial Dysfunction

  2025cites this paper
• Resolution of inflammation in pulmonary arterial hypertension, the influence of sex—An IUPHAR immunopharmacology committee review

  2025cites this paper
• Vascular effects of perivascular adipose tissue-derived chemerin in obesity-associated cardiovascular disease

  2025cites this paper
• Linking Lipid Metabolism and Immune Function: New Insights into Chronic Respiratory Diseases

  2025cites this paper
• Relationship of Serum Chemerin Concentrations with Coronary Slow Flow: A Pathophysiological and Clinical Analysis.

  2025cites this paper
• Omega‐3 polyunsaturated fatty acids and pulmonary arterial hypertension: Insights and perspectives

  2024cites this paper
• Dynamic changes in proresolving lipid mediators and their receptors following acute vascular injury in male rats

  2024cites this paper
• Resolution of inflammation, an active process to restore the immune microenvironment balance: A novel drug target for treating arterial hypertension.

  2024cites this paper
• Decreased plasma docosahexaenoic acid concentration in chronic obstructive pulmonary disease patients with pulmonary Hypertension: Findings from human lipidomics and transcriptomics analysis.

  2024cites this paper
• Impact of Resolvin-E1 and Maresin-1 on Bone Marrow Stem Cell Osteogenesis under Inflammatory Stress

  2024cites this paper
• Resolvin D2 prevents vascular remodeling, hypercontractility and endothelial dysfunction in obese hypertensive mice through modulation of vascular and proinflammatory factors.

  2024cites this paper
• Chemerin as a cardiovascular biological marker: Present and future

  2023cites this paper
• Bioactive lipids in hypertension.

  2023cites this paper
• Specialized pro-resolving mediator therapy improves vascular relaxation via formyl peptide-receptor-2.

  2023cites this paper
• Nitrite Supplementation Restores Aortic Health in Chronically Stressed Mice

  2023cites this paper
• Resolvin D1 attenuates Ang II-induced hypertension in mice by inhibiting the proliferation, migration and phenotypic transformation of vascular smooth muscle cells by blocking the RhoA/mitogen-activated protein kinase pathway

  2023cites this paper
• Effect of specialized pro-resolving lipid mediators in the regulation of vascular tone and inflammation in human saphenous vein.

  2023cites this paper
• Inflammation Resolution in the Cardiovascular System: Arterial Hypertension, Atherosclerosis, and Ischemic Heart Disease

  2023cites this paper
• DHA, RvD1, RvD5, and MaR1 reduce human coronary arteries contractions induced by PGE2.

  2022cites this paper
• Role of Chemerin/ChemR23 axis as an emerging therapeutic perspective on obesity-related vascular dysfunction

  2022cites this paper
• Specialized Pro-Resolving Lipid Mediators: New Therapeutic Approaches for Vascular Remodeling

  2022cites this paper
• Specialized pro-resolution mediators in the bladder: Receptor expression and recovery of bladder function from cystitis

  2022cites this paper
• Protective Potential of Maresins in Cardiovascular Diseases

  2022cites this paper
• Resolvin D2 Attenuates Cardiovascular Damage in Angiotensin II-Induced Hypertension

  2022cites this paper
• Role of Chemerin in Cardiovascular Diseases

  2022cites this paper
• Roles of Resolvins in Chronic Inflammatory Response

  2022cites this paper
• Anti-Inflammatory Effect of Specialized Proresolving Lipid Mediators on Mesenchymal Stem Cells: An In Vitro Study

  2022cites this paper
• Specialized Pro-Resolving Lipid Mediators in Neonatal Cardiovascular Physiology and Diseases

  2021cites this paper
• Resolvin D2 and Resolvin D1 Differentially Activate Protein Kinases to Counter-Regulate Histamine-Induced [Ca2+]i Increase and Mucin Secretion in Conjunctival Goblet Cells

  2021cites this paper
• Resolvin E1 Attenuates Pulmonary Hypertension by Suppressing Wnt7a/β-Catenin Signaling

  2021cites this paper
• Resolvin-D1 attenuation of Angiotensin II-induced cardiac inflammation in mice is associated with prevention of cardiac remodeling and hypertension.

  2021cites this paper
• Docosahexaenoic acid inhibits U46619- and prostaglandin F2α-induced pig coronary and basilar artery contractions by inhibiting prostanoid TP receptors.

  2021cites this paper
• EXPERIMENTAL STUDIES OF LIPID MEDIATOR MODULATION OF AIRWAY RESPONSIVENESS

  2021cites this paper
• Specialized pro-resolving lipid mediators in cardiovascular disease, diagnosis, and therapy.

  2020cites this paper
• Eicosapentaenoic acid ameliorates pulmonary hypertension via inhibition of tyrosine kinase Fyn.

  2020cites this paper
• Effect of Omega-3 Polyunsaturated Fatty Acids in Modulation of Vascular Tone under Physiological and Pathological Conditions.

  2020cites this paper
• Molecular Dynamics Simulations Provide Insight into the Loading Efficiency of Pro-Resolving Lipid Mediators Resolvin D1 and D2 in Cell Membrane-Derived Nanovesicles.

  2020cites this paper
• Investigation of the mechanisms underlying the vascular relaxation mediated by n-3 PUFAs (fish oils), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), in resistance and conduit arteries

  2019influential citation
• G-Protein Coupled Receptor Targeting on Myeloid Cells in Atherosclerosis

  2019cites this paper
• Pro-resolving lipid mediators in vascular disease.

  2018cites this paper
• Resolvin E1, resolvin D1 and resolvin D2 inhibit constriction of rat thoracic aorta and human pulmonary artery induced by the thromboxane mimetic U46619

  2018cites this paper